Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Major Congenital Malformations after First-Trimester Exposure to ACE Inhibitors

Open access
Cooper, William O., Hernandez-Diaz, Sonia, Arbogast, Patrick G., Dudley, Judith A., Dyer, Shannon, Gideon, Patricia S., Hall, Kathi, Ray, Wayne A. · 2006 · New England Journal of Medicine

Abstract

BACKGROUND: Use of angiotensin-converting-enzyme (ACE) inhibitors during the second and third trimesters of pregnancy is contraindicated because of their association with an increased risk of fetopathy. In contrast, first-trimester use of ACE inhibitors has not been linked to adverse fetal outcomes. We conducted a study to assess the association between exposure to ACE inhibitors during the first trimester of pregnancy only and the risk of congenital malformations. METHODS: We studied a cohort of 29,507 infants enrolled in Tennessee Medicaid and born between 1985 and 2000 for whom there was no evidence of maternal diabetes. We identified 209 infants with exposure to ACE inhibitors in the first trimester alone, 202 infants with exposure to other antihypertensive medications in the first trimester alone, and 29,096 infants with no exposure to antihypertensive drugs at any time during gestation. Major congenital malformations were identified from linked vital records and hospitalization claims during the first year of life and confirmed by review of medical records. RESULTS: Infants with only first-trimester exposure to ACE inhibitors had an increased risk of major congenital malformations (risk ratio, 2.71; 95 percent confidence interval, 1.72 to 4.27) as compared with infants who had no exposure to antihypertensive medications. In contrast, fetal exposure to other antihypertensive medications during only the first trimester did not confer an increased risk (risk ratio, 0.66; 95 percent confidence interval, 0.25 to 1.75). Infants exposed to ACE inhibitors were at increased risk for malformations of the cardiovascular system (risk ratio, 3.72; 95 percent confidence interval, 1.89 to 7.30) and the central nervous system (risk ratio, 4.39; 95 percent confidence interval, 1.37 to 14.02). CONCLUSIONS: Exposure to ACE inhibitors during the first trimester cannot be considered safe and should be avoided.

Overview

Integrity signals

Registry

Crossref · 10.1056/nejmoa055202

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 34 references

Cited by

See all 1,192

Metadata

Authors
Cooper, W. O., Hernandez-Diaz, S., Arbogast, P. G., Dudley, J. A., Dyer, S., Gideon, P. S., Hall, K., & Ray, W. A.
Affiliations
Vanderbilt University (US)
Venue
New England Journal of Medicine
Published
2006-06-08
Volume
354
Issue
23
Pages
2443-2451
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2130567407
Cited by
1,192
References
34
Citations by year
2026: 14 · 2025: 14 · 2024: 24 · 2023: 31 · 2022: 44 · 2021: 32 · 2020: 45 · 2019: 55 · 2018: 64 · 2017: 93 · 2016: 54 · 2015: 66 · 2014: 61 · 2013: 70 · 2012: 98
FWCI
88.22
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Agency for Healthcare Research and Quality (HS 10384)
  • U.S. Public Health Service (223-02-3003)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Prenatal Substance Exposure Effects
Keywords
ACE inhibitors, first trimester drug exposure, congenital malformations, antihypertensive drugs, cardiovascular anomalies, central nervous system malformations
MeSH terms
Abnormalities, Drug-Induced, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Female, Heart Defects, Congenital, Humans, Infant, Newborn, Nervous System Malformations, Pregnancy, Pregnancy Trimester, First, Risk, Cohort Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Major Congenital Malformations after First-Trimester Exposure to ACE Inhibitors. https://app.cochat.ai/papers/10.1056/nejmoa055202
The paper
Cooper, W. O., Hernandez-Diaz, S., Arbogast, P. G., Dudley, J. A., Dyer, S., Gideon, P. S., Hall, K., & Ray, W. A. (2006). Major Congenital Malformations after First-Trimester Exposure to ACE Inhibitors. New England Journal of Medicine. https://doi.org/10.1056/nejmoa055202

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.